An in vivo small-molecule drug screen in developing zebrafish larvae identifies dozens of unique chemical modulators capable of reducing atherogenic apolipoprotein B levels.
Restoring endolysosomal membrane fluidity limits tau seed escape, seeded aggregation, and neuronal toxicity in cell and animal models.